Related references
Note: Only part of the references are listed.TGFβ biology in cancer progression and immunotherapy
Rik Derynck et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1
Preeti Narayan et al.
CLINICAL CANCER RESEARCH (2020)
A Potent Pan-TGFβ Neutralizing Monoclonal Antibody Elicits Cardiovascular Toxicity in Mice and Cynomolgus Monkeys
Mayur S. Mitra et al.
TOXICOLOGICAL SCIENCES (2020)
CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer
Bruna Cerbelli et al.
VIRCHOWS ARCHIV (2020)
CD73 promotes tumor metastasis by modulating RICS/RhoA signaling and EMT in gastric cancer
Zhijun Xu et al.
CELL DEATH & DISEASE (2020)
Targeting CD73 to augment cancer immunotherapy
Meejeon Roh et al.
CURRENT OPINION IN PHARMACOLOGY (2020)
Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody-Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function
Rui Jin et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer
Bruna Cerbelli et al.
CANCERS (2020)
Breast cancer-derived exosomes transmit lncRNA SNHG16 to induce CD73+γδ1 Treg cells
Chao Ni et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Mesenchymal Stromal Cells Derived from Normal Cervix and Cervical Cancer Tumors Increase CD73 Expression in Cervical Cancer Cells Through TGF-β1 Production
Luis Roberto Avila-Ibarra et al.
STEM CELLS AND DEVELOPMENT (2019)
Cervical cancer cells produce TGF-β1 through the CD73-adenosine pathway and maintain CD73 expression through the autocrine activity of TGF-β1
Rosario Garcia-Rocha et al.
CYTOKINE (2019)
CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy
Siqi Chen et al.
NATURE COMMUNICATIONS (2019)
TGF-beta plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating sternness, EMT and apoptosis
Xiaodan Xu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
Julius Strauss et al.
CLINICAL CANCER RESEARCH (2018)
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
Yan Lan et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGF beta enhance the efficacy of cancer immunotherapy
Rajani Ravi et al.
NATURE COMMUNICATIONS (2018)
Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial
L. Buisseret et al.
ANNALS OF ONCOLOGY (2018)
Pharmacological and immunological targeting of tumor mesenchymalization
Justin M. David et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Role of transforming growth factor-β1 in triple negative breast cancer patients
Mingxia Zhang et al.
INTERNATIONAL JOURNAL OF SURGERY (2017)
Pathological expression of tissue factor confers promising antitumor response to a novel therapeutic antibody SC1 in triple negative breast cancer and pancreatic adenocarcinoma
Xuesai Zhang et al.
ONCOTARGET (2017)
MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy
Julia Reinhardt et al.
CANCER RESEARCH (2017)
Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action
James C. Geoghegan et al.
MABS (2016)
Targeting CD73 in the tumor microenvironment with MEDI9447
Carl M. Hay et al.
ONCOIMMUNOLOGY (2016)
CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer
Martin Turcotte et al.
CANCER RESEARCH (2015)
Robust enumeration of cell subsets from tissue expression profiles
Aaron M. Newman et al.
NATURE METHODS (2015)
A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer
Allen Cohn et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Role of TGF-β Signaling in Generation of CD39+CD73+ Myeloid Cells in Tumors
Sergey V. Ryzhov et al.
JOURNAL OF IMMUNOLOGY (2014)
Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
Bertrand Allard et al.
CLINICAL CANCER RESEARCH (2013)
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
Sherene Loi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma
Xiao-Xia Lu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
Stat3 and Gfi-1 Transcription Factors Control Th17 Cell Immunosuppressive Activity via the Regulation of Ectonucleotidase Expression
Fanny Chalmin et al.
IMMUNITY (2012)
High expression of CD73 as a poor prognostic biomarker in human colorectal cancer
Xian-Rui Wu et al.
JOURNAL OF SURGICAL ONCOLOGY (2012)
Pattern of metastatic spread in triple-negative breast cancer
Rebecca Dent et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
The basics of epithelial-mesenchymal transition
Raghu Kalluri et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Simultaneous visualization of multiple antigens with tyramide signal amplification using antibodies from the same species
Zsuzsanna E. Toth et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2007)
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Richard M. Neve et al.
CANCER CELL (2006)
Share Paper
